Skip navigation

Avacta Group plc announces the appointment of Dr Eliot Forster as Non-Executive Chairman

11 June 2018

Wetherby and Cambridge, UK, 11 June 2018: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce the appointment of Dr Eliot Forster as Non-Executive Chairman to the Board with immediate effect.  Dr Trevor Nichols, who has acted as Chairman of the Board since January 2014, will remain on the Board as a Non-Executive Director.

Dr Forster brings over 25 years of experience in the pharmaceutical and biotechnology industry, most recently leading Immunocore as Chief Executive Officer to become a world-leading immuno-oncology biotech, raising over £230 million in equity and non-dilutive funding as well as securing partnerships with AstraZeneca and the Bill & Melinda Gates Foundation.

The early part of Dr Forster’s career was at GSK and then he went on to hold a number of senior roles in Pfizer where he became Head of Development and Operations for the EU and Asia, a role in which he was responsible for drug development activities across multiple geographies and was involved in bringing several drugs to market, including Celebrex® (celecoxib) and Relpax® (eletriptan).  Since leaving Pfizer, Dr Forster’s roles have included the Chief Executive Officer of UK-based Creabilis.

Dr Forster holds a PhD in neurophysiology from Liverpool University and an MBA from Henley Management College.  He is Chairman of the MedCity project that promotes the Life Sciences in the London/Cambridge/Oxford “Golden Triangle”. He is an Honorary Visiting Professor of the Pharmacology and Physiology Department at the University of Liverpool, a Board member of OSCHR (Office for Strategic Coordination of Health Research) and the National Genomics Board.

Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented: “I am absolutely delighted that Dr Forster is joining Avacta.  We have an exciting opportunity to build a world-leading and highly valuable biotech based on the Affimer platform.  Eliot’s considerable experience, expertise and network will make a material difference to achieving that goal and to delivering maximum value to shareholders.

I would like to thank Dr Nichols for his hard work and support as Chairman over the past few years. We are very pleased that he will remain on the Board as Non-Executive Director.

I look forward to updating the market on Avacta’s progress as the Group advances its proprietary pipeline of Affimer therapeutics towards the clinic and builds a business based on Affimer reagents for research and diagnostics.”

Dr Eliot Forster, Chairman of Avacta Group, commented:
“I am very much looking forward to serving Avacta Group alongside the Board of Directors.   I am confident that Avacta’s Affimer technology will be both disruptive and transformational in the biotech field.  It is a privilege to begin working with Alastair and the team as the Company enters an exciting new phase in its growth, advancing therapeutics to the clinic and further building the reagents business."


For further information from Avacta Group plc, please contact:
Avacta Group plc
Alastair Smith, Chief Executive Officer
Tony Gardiner, Chief Financial Officer
Tel:  +44 (0) 844 414 0452 

Zyme Communications (Trade and Regional Media)
Katie Odgaard

Yellow Jersey (Financial Media and IR)
Sarah Hollins Tel: +44 (0)7787 502 947  

Tel: +44 (0)7764 947137

finnCap Ltd
Geoff Nash / Giles Rolls - Nominated Adviser
Tim Redfern / Nikita Jain - Corporate Broking

WG Partners
Nigel Birks / Nigel Barnes
David Wilson / Claes Spang

Tel:  +44 (0) 207 220 0500

Tel:  +44 (0) 203 705 9318
Tel:  +44 (0) 203 705 9217

To opt-out from receiving press releases from Zyme Communications please email To view our privacy policy please click here.

About Avacta Group plc (
Avacta’s principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal’s immune response, poor specificity in many cases, and batch to batch variability.  Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets. 

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
Regulatory disclosure - The following information is disclosed in accordance with Rule 17 and paragraph (g) of Schedule 2 of the AIM Rules for Companies.
Dr Eliot Richard Forster, 52, holds no ordinary share in the Company. Mr. Forster’s current and previous directorships are as follows:
Current Directorships/Partnerships:
MedCity Ltd
GERM Limited
Advanced Oxford CIC
Biobreak UK Limited
GMEC Management Company Limited 

Directorships/Partnerships held in last 5 years:
Immunocore Nominees Limited
Creabilis Holdings Limited
Creabilis UK Limited
Immunocore Limited
Persica Pharmaceuticals Limited
Spinifex Inc.
Oxford Biotherapeutics Ltd
Poet in the City Trading Limited
Voluntary liquidation
Solace Pharmaceuticals Inc. was put into liquidation on 8 February 2010. Mr. Forster resigned in May 2010.
Save for the disclosures above, there are no further disclosures to be made in accordance with Rule 17 and Schedule 2(g) of the AIM Rules.